| Revenue growth | 23.6% YoY overall; 13.7% organic growth in FY26. |
|---|---|
| Margins | Margins expanded 140bps to 25.9%; target 27-28% group margin. |
| Demand visibility | Strong underlying demand across wellness, specialty, and routine testing. |
| Management confidence | High; citing structural moat and successful M&A integration playbook. |
Growth
FY26 revenue grew 23.6% to ₹1,646cr. Organic revenue grew 13.7% with 25.9% normalized margins.
Outlook
3-year revenue CAGR guidance of 14-15%; target EBITDA margin 27-28%; plans for 1,500 new centers.
Risks
Integration of single-lab acquisitions; competition in specialty segments; maintaining high-end quality standards during expansion.
Earnings Call filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹541.45
- Market cap
- ₹11,233 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 55.7×Sector 53.1×
- Promoter holding
- 48.86%-0.01% QoQ
- FII holding
- 11.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Employee Stock Options
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare Merger & Restructuring Worth ₹1.26 Cr
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
- Value
- ₹1.26 Cr
Metropolis Healthcare Capital Structure Change
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare Merger & Restructuring Worth ₹1.25 Cr
Metropolis Healthcare transferred its External Quality Assessment Services Division to subsidiary MQSPL for ₹1.25 Crore. The transfer was executed via a slump sale.
- Value
- ₹1.25 Cr
Metropolis Healthcare Merger & Restructuring Worth ₹0.01 Cr
Metropolis Healthcare's subsidiary, MQSPL, will issue 10,000 Optionally Convertible Redeemable Preference Shares (OCRPS) to Dr. Puneet Kumar Nigam. Post-conversion, MQSPL will remain a subsidiary.
- Value
- ₹0.01 Cr
Metropolis Healthcare Annual General Meeting
Metropolis Healthcare held its 26th Annual General Meeting on August 18, 2026. Shareholders reviewed financial statements and confirmed previous interim dividend payments.